Your Health, We Care
Asciminib is a targeted inhibitor of BCR-ABL1 tyrosine kinase, mainly used for the treatment of blood diseases such as chronic myeloid leukemia (CML), initially developed and produced by Novartis.
The Asciminib drug developed and produced by Lucius has a specification of 40mg * 60tablets and a price of approximately $621 per box. The drug price may vary due to factors such as region, sales channels, and promotional activities.
